PRESS RELEASE published on 02/10/2026 at 07:30, 2 months 18 days ago Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026 Nicox to present NCX 470 Phase 3 data at AGS Annual Meeting 2026 with podium presentations showcasing clinical study results and efficacy of the ophthalmic solution Clinical Study Ophthalmology Nicox NCX 470 AGS Annual Meeting 2026
BRIEF published on 01/20/2026 at 07:35, 3 months 11 days ago Nicox announces its participation in several congresses in 2026 Glaucoma Ophthalmology Nicox NCX 470 Congress 2026
BRIEF published on 01/20/2026 at 07:35, 3 months 11 days ago Nicox Announces 2026 Conference Participation and Data Presentations Scientific Data Ophthalmology NCX 470 Conference Participation 2026 Events
PRESS RELEASE published on 01/20/2026 at 07:30, 3 months 11 days ago Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations Nicox to attend key ophthalmology conferences and present scientific data at AGS 2026 Annual Meeting. Management team available for meetings. Developing innovative eye health solutions Conference Scientific Data Ophthalmology Nicox Eye Health
BRIEF published on 12/16/2025 at 07:35, 4 months 15 days ago Nicox Finalizes Key Data for NCX 470 NDA Submission by H1 2026 Clinical Trials Ophthalmology Nicox NCX 470 NDA Submission
PRESS RELEASE published on 12/16/2025 at 07:30, 4 months 15 days ago Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 Nicox completes key data generation for NCX 470 new drug application submission in H1 2026, including clinical trial and stability data. U.S. and China submissions on track FDA Clinical Trials Nicox NCX 470 New Drug Application
BRIEF published on 10/23/2025 at 07:35, 6 months 8 days ago Nicox Releases First Half 2025 Financial Results Financial Results Debt Repayment Ophthalmology Cost Control NCX 470
PRESS RELEASE published on 10/23/2025 at 07:30, 6 months 8 days ago Nicox Provides First Half 2025 Financial Results Nicox provides first half 2025 financial results, expects NDA submissions for NCX 470 in 2026. Company aims to finance operations for 12 months and repay debts by 2026 Financial Results Debt Repayment Nicox NCX 470 NDA Submissions
BRIEF published on 10/02/2025 at 07:35, 6 months 29 days ago Nicox: Positive results for NCX 470 in the Denali study Clinical Trial Ophthalmology Nicox NCX 470 Intraocular Pressure
PRESS RELEASE published on 10/02/2025 at 07:30, 6 months 29 days ago Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Nicox's NCX 470 shows sustained efficacy with no new safety concerns in Denali trial. Data presented at upcoming ophthalmology conferences Nicox NCX 470 Denali Trial Ophthalmology Conferences Sustained Efficacy
Published on 05/01/2026 at 04:00, 33 minutes ago Jericho Energy Ventures Announces Short Delay in Filing of 2025 Annual Financial Statements
Published on 05/01/2026 at 03:25, 1 hour 8 minutes ago McEwen Inc. and Golden Lake Exploration Inc. Announce Closing of Arrangement
Published on 05/01/2026 at 02:55, 1 hour 38 minutes ago GLG Life Tech Corporation Reports 2025 Annual & Fourth Quarter Financial Results
Published on 05/01/2026 at 01:00, 3 hours 33 minutes ago PPX Mining Announces Grant of Stock Options, Restricted Share Units and Deferred Share Units
Published on 05/01/2026 at 00:45, 3 hours 48 minutes ago Inventus Announces Closing of $2.5 Million Non-Brokered Flow-Through Financing
Published on 04/30/2026 at 23:39, 4 hours 54 minutes ago Anemoi International Ltd: Final Results For Year Ended 31 December 2025
Published on 04/30/2026 at 22:35, 5 hours 58 minutes ago Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma
Published on 04/30/2026 at 22:04, 6 hours 29 minutes ago Interim individual financial statements for the period ending on March 31, 2026 of Sirma Group Holding JSC
Published on 04/30/2026 at 19:00, 9 hours 32 minutes ago DOUGLAS Group grows sales in Q2 and updates full-year guidance on adjusted EBITDA
Published on 04/30/2026 at 19:00, 9 hours 33 minutes ago BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
Published on 04/30/2026 at 20:00, 8 hours 32 minutes ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 9 hours 17 minutes ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 9 hours 33 minutes ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 10 hours 23 minutes ago Minutes of the Combined General Meeting held on April 30, 2026
